Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 11/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.44 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11326712 | 0.92 | ALK (0.51) | JAK2ALKEGFR | |
| SCHEMBL15794995 | 0.88 | ALK (0.52) | JAK2ALKEGFR | |
| SCHEMBL11296289 | 0.87 | ALK (0.50) | JAK2TNK2SRCALKPTK2 | |
| SCHEMBL15794966 | 0.86 | ALK (0.56) | JAK2ALKNUAK1 | |
| SCHEMBL11330849 | 0.83 | ALK (0.52) | JAK2ALKPTK2EGFR | |
| SCHEMBL11406921 | 0.83 | ALK (0.57) | JAK2ALKEGFR | |
| SCHEMBL11297437 | 0.83 | ALK (0.51) | JAK2TNK2SRCALKPTK2 | |
| SCHEMBL15795013 | 0.82 | JAK2 (0.49) | JAK2ALK | |
| SCHEMBL15795133 | 0.81 | JAK2 (0.51) | JAK2ALK | |
| SCHEMBL11302133 | 0.80 | ALK (0.51) | JAK2ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | claimed |
| EP-2665725-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | claimed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2665725-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097479-A1 | BICYCLIC INHIBITORS OF ANAPHASTIC LYMPHOMA KINASE | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | JAK2 104/4885TNK2 129/4885SRC 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.